What is Ranibizumab

Ranibizumab is a recombinant humanized monoclonal antibody fragment designed to bind to all active isoforms of vascular endothelial growth factor (VEGF).

It is approved for the treatment of patients with macular edema after retinal vein occlusion (RVO), neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, and myopic choroidal neovascularization (CNV). 

Inhibition of VEGF with ranibizumab results in blockage of both vessel permeability and angiogenesis.

Ranibizumab was FDA-approved in June 2006.

Brand Name



  • choroidal neovascularization (CNV)
  • diabetic macular edema
  • diabetic retinopathy
  • macular degeneration
  • macular edema following retinal vein occlusion

For the treatment of neovascular (wet) age-related macular degeneration (AMD)

Side Effects

  1. anemia
  2. antibody formation
  3. arthralgia
  4. atrial fibrillation
  5. blepharitis
  6. blurred vision
  7. cataracts
  8. conjunctival hyperemia
  9. constipation
  10. cough
  11. endophthalmitis
  12. gastroesophageal reflux
  13. headache
  14. hypercholesterolemia
  15. hyperemia
  16. impaired wound healing
  17. influenza
  18. injection site reaction
  19. lacrimation
  20. myocardial infarction
  21. nausea
  22. ocular hemorrhage
  23. ocular hypertension
  24. ocular infection
  25. ocular inflammation
  26. ocular irritation
  27. ocular pain
  28. ocular pruritus
  29. peripheral edema
  30. peripheral neuropathy
  31. pharyngitis
  32. renal failure (unspecified)
  33. retinal detachment
  34. sinusitis
  35. stroke
  36. thromboembolism

Monitoring Parameters

  • intraocular pressure


  • breast-feeding
  • children
  • geriatric
  • glaucoma
  • increased intraocular pressure
  • infants
  • neonates
  • ocular infection
  • ocular surgery
  • pregnancy


There are no drug interactions associated with Ranibizumab products.


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top